INFLAMMATORY BIOMARKER ASSOCIATED VARIABILITY IN THE PHARMACODYNAMIC RESPONSE TO GABAPENTIN IN DIABETIC PERIPHERAL NEUROPATHY

Abstract

Background: Chronic neuropathic pain is largely caused by diabetic peripheral neuropathy (DPN), a frequent microvascular condition associated with diabetes mellitus. Gabapentin is widely used for the management of painful DPN; however, its pharmacodynamic response may vary depending on the severity of neuropathy and clinical status of the patient. To evaluate the pharmacodynamic profile of gabapentin with reference to diabetic peripheral neuropathy status. Methods: A prospective, observational, comparative analytical investigation was carried out involving 76 patients, with 19 individuals in each of the four study groups: non-diabetic individuals with neuropathy, diabetic patients experiencing non-diabetic neuropathies, diabetic patients suffering from diabetic peripheral neuropathy, and diabetic peripheral neuropathy patients undergoing emergency surgical procedures. The pharmacodynamic evaluation included assessing pain intensity using the Visual Analogue Scale (VAS), along with glycaemic parameters and inflammatory biomarkers. The results were analyzed and compared across the four different study groups. Results: Patients suffering from diabetic peripheral neuropathy showed notably elevated pain levels, less effective glycaemic control, and altered levels of inflammatory biomarkers when compared to the other groups (P < 0.05).The greatest pharmacodynamic changes were observed in patients with diabetic peripheral neuropathy undergoing emergency surgery. These findings indicate that the clinical response to gabapentin varies according to DPN status. Conclusion: The pharmacodynamic profile of gabapentin differs with extentof DPN. Individualized treatment based on neuropathy status may improve pain control and optimize therapeutic outcomes.